TARS Tarsus Pharmaceuticals, Inc.

XNAS 77.90 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

TARS $77.90 —

What changed

Recent filings, trades and moves
Key stats
$77.90
52-Week Range
$53.89 – $91.53
YTD
-3.55%
IV Rank (30D)
48.77
Straddle Price
$10.85
P/C Vol Ratio
0.74
Market Cap
$3.7B
Open
$75.73
Day Range
$75.61 – $78.08
Volume
387,383
Prev Close
$75.95
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)5.12%
Beta vs SPY0.78
Cost of Equity (CAPM)9.04% (VRP-adj)
WACC8.81%
Volatility Risk Premium+30.1pp (IV − HV30)
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+28.3%
DCF Horizon10 years explicit + fade
Forward Tilt (NTM/TTM)×1.10 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$0.0B
Return on Equity (TTM)-675.5%
Book / Price3.0%
Gross Margin (TTM)93.2%
FCF Margin (TTM)4.8%
Debt / Equity0.70
Quality Score2/6 — normal (10y DCF)
SMA 50$74.29 (Market Anchor value)
SMA 20 / Bollinger Mid$73.24
Bollinger Width / SMA2019.8% (drives anchor stability)
Net Debt$-0.1B
Market Cap$4B
Peers used for multiples: AMGN, BIIB, GILD, JNJ, LLY, PFE, REGN, UTHR
60-Day Conviction
59%
20-Day Fair Value
≈ by Dec 18, 2026
$76.97
α +0.1% rank 42%
conviction
16%
40-Day Fair Value
≈ by Jan 18, 2027
$77.50
α +0.8% rank 46%
conviction
56%
60-Day Fair Value
≈ by Feb 16, 2027
$77.91
α +1.4% rank 39%
conviction
59%
MethodImplied PriceWeightDetail
DCF $51.45 15%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 40.2× · 7 peers
Peer EV/EBITDA n/a 0% median 19.7× · 8 peers
Peer P/B $13.66 12% median 6.1× · 8 peers
Peer P/S $106.05 12% median 6.6× · 8 peers
Market Anchor (SMA50) $74.29 31% stability 51% (BB-width)
Options Expected (B-L 30d) $74.19 30% 26 strikes · skew +0.19
As of 2026-11-19 · updated
About
Industry (SIC)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
Exchange
XNAS
Market Cap
$3.7B
Employees
370
List Date
2020-10-16
CIK
0001819790
Last Earnings
Nov 3 after close · −4.9% vs ±15.0% expected
Next Earnings
~Feb 22, 2027 (estimated)
Headquarters
Irvine, CA
Homepage
https://www.tarsusrx.com

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart

Markers: Click a marker type to show or hide it. Earnings turn amber when the stock moved more than options implied; hollow markers are still to come, or insider trades under a 10b5-1 plan. Intraday times are New York time; shaded bars are pre-market and after-hours.

Seasonality
Month'21'22'23'24'25'26Avg
Jan-9.83%-17.34%9.29%35.12%-2.52%-20.09%-0.90%
Feb-6.19%-14.58%-1.02%32.16%-17.84%14.55%1.18%
Mar-12.39%-11.89%-17.95%-1.62%20.25%-9.40%-5.50%
Apr-6.71%6.45%18.70%-12.33%6.11%-9.41%0.47%
May4.39%-1.79%10.05%1.45%-14.61%-6.63%-1.19%
Jun-18.76%6.96%5.92%-16.70%-7.62%6.80%-3.90%
Jul-22.17%-0.07%27.23%-13.99%-2.93%-2.66%-2.43%
Aug17.94%0.52%-4.16%15.71%43.54%21.07%15.77%
Sep-15.52%11.60%6.66%25.68%1.43%6.16%6.00%
Oct28.10%8.35%-18.35%37.78%20.00%-0.81%12.51%
Nov-5.84%-6.19%13.92%10.89%14.57%4.29%*5.27%
Dec-7.37%-13.25%27.68%9.82%2.39%--3.85%
Total-49.20%-31.24%89.69%173.16%60.37%-3.04%39.96%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $73.49
SMA 50: $74.21
SMA 200: $68.21
Current: $77.06
EMA 12: $75.62
EMA 26: $74.30
MACD: 1.3163 | Signal: 0.6681
BULLISH
ADX (14): 18.36
RANGE
+DI: 23.36
−DI: 14.50

Momentum Oscillators

RSI (14): 56.26
NEUTRAL
Stoch %K: 73.26
Stoch %D: 78.63
Williams %R: -26.80

Volume & Volatility

BB Upper: $80.90
BB Lower: $66.07
NEUTRAL
OBV: 9,044,426
Vol SMA 20: 820,577
Vol ROC: -88.36%
ATR: $3.69
True Range: $2.33
HV 20: 46.6%
HV 30: 45.0%
HV 60: 49.5%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-11-20T00:00:00 – 2026-11-18T00:00:00
AI Analysis
Written before TARS’s Nov 3 earnings report, so it doesn’t reflect the results.

LLM Stock Analysis Report

Executive Summary

Overall Assessment: NEUTRAL (Confidence Level: 6/10)

Key Drivers:

  • Strong fundamental performance with low volatility
  • Bullish sentiment from recent news headlines
  • Technical indicators signal a potentially range-bound market

Primary Risks:

  • Low earnings estimates could impact stock price
  • Volatility may increase if market conditions change

Investment Thesis:

Tarsus (TARS) is a fundamentally strong company with a stable share price. Recent news headlines suggest bullish sentiment, which aligns with the technical indicators' neutral signal. The options market expects a moderate move by expiration, indicating potential for continued stability.

Recent News Sentiment Impact:

The recent news headlines have a positive overall sentiment, highlighting Tarsus's participation in investor conferences and product advancements. These events may contribute to the company's stable share price.

Technical Analysis

Trend Direction: NEUTRAL (Short-term: range-bound, Medium-term: uptrend, Long-term: uptrend)

Support/Resistance Levels:

  • Lower Bollinger Band: $59.36
  • Middle Bollinger Band: $62.84
  • Upper Bollinger Band: $66.33

Momentum Signals:

  • RSI: 45.59 (neutral)
  • MACD: -0.88 / Signal: 0.26 / Histogram: -1.14 (bearish)

Volume Analysis:

  • Volume SMA 20: 742038.55
  • On-Balance Volume (OBV): 12628526.74
  • Volume Rate of Change: -74.17%

News & Sentiment Analysis

Recent Headlines Summary:

Tarsus's recent news headlines are primarily positive, highlighting the company's participation in investor conferences and product advancements.

Sentiment Assessment: POSITIVE

Catalyst Identification:

Upcoming earnings reports may impact stock price.

Market Narrative:

The news headlines align with the technical indicators' neutral signal, indicating a potentially range-bound market.

Risk & Volatility Assessment

Risk Interpretation: LOW (Beta: 0.79, Alpha: 0.27)

Volatility Regime: LOW (Stock Volatility: 0.44)

Options Market Signals:

  • IV Rank: 19.4% (Low)
  • Current IV: 73.5%
  • Expected Move: $7.75 (27 DTE), 7-DTE: $7.75
  • Volume Flow: 253 calls vs 13 puts
  • Open Interest: 254 calls vs 1,166 puts
  • Put/Call Volume Ratio: 0.05 (Bullish sentiment)

Downside Protection:

Support levels are in place at the lower Bollinger Band ($59.36), providing some downside protection.

Market Context & Positioning

Sector Performance:

Tarsus is performing relatively well within its sector, with a strong fundamental performance and low volatility.

Institutional Activity:

Volume patterns suggest institutional interest in Tarsus.

Correlation Analysis:

The stock moves relatively less than the market (R-squared interpretation), indicating a potentially defensive position.

Relative Valuation:

Tarsus's current price is relatively stable within its trading range, indicating a potentially neutral positioning.

Key Levels & Action Items

Critical Price Levels:

  • Lower Bollinger Band: $59.36
  • Middle Bollinger Band: $62.84
  • Upper Bollinger Band: $66.33

Breakout/Breakdown Levels:

  • SMA 20: $62.84 (support)
  • SMA 50: $65.87 (resistance)

Time-Sensitive Catalysts:

Earnings reports may impact stock price.

Risk Management:

Stop-loss levels and position sizing considerations should be based on the recent range-bound market conditions.

Please note that this report is intended for educational purposes only and does not constitute investment advice or recommendations.

Generated
Earnings History
15 of 15 under expected move
Avg Expected Move
19.62%
Avg Actual Move
5.97%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2023-03-13 After-Close 41.72% 0.85% 0.02x Within
2023-05-09 After-Close 16.16% 3.79% 0.23x Within
2023-11-09 After-Close 36.48% 12.20% 0.33x Within
2024-02-27 After-Close 14.30% 3.44% 0.24x Within
2024-05-08 After-Close 18.07% 8.86% 0.49x Within
2024-08-08 After-Close 18.00% 13.72% 0.76x Within
2024-11-13 After-Close 23.38% 0.31% 0.01x Within
2025-02-25 Pre-Market 18.23% 9.33% 0.51x Within
2025-05-01 Pre-Market 14.79% 3.10% 0.21x Within
2025-08-06 After-Close 17.23% 15.15% 0.88x Within
2025-11-04 After-Close 15.03% 4.62% 0.31x Within
2026-02-23 After-Close 17.60% 7.79% 0.44x Within
2026-05-06 After-Close 15.75% 1.24% 0.08x Within
2026-08-05 Pre-Market 12.52% 0.29% 0.02x Within
2026-11-03 After-Close 15.01% 4.91% 0.33x Within

Earnings calendar: this week’s reports with expected vs actual moves →

TARS Options Activity & IV Rank

TARS IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 61.1%
7-DTE IV: —
Expected Move: $10.85
7-DTE Move: $4.50
Days to Exp: 29 (2026-12-18)

Options Flow · All expiries

Call Volume: 489
Put Volume: 360
P/C Volume: 0.736
NEUTRAL
Call OI: 1,630
Put OI: 1,076
P/C OI: 0.66
Total OI: 2,706

ATM Options Pricing

ATM Call: $5.35
ATM Put: $5.50
Call %: 6.9%
Put %: 7.1%

Chain Summary

Chain Volume: 849
Chain OI: 2,706
Last Updated: 11/19/2026

TARS Implied Volatility

30-day IV
61.1%
Nov 19
IV rank
49Medium
Within its 90-session range

Loading implied volatility…

The 30-day IV is the at-the-money implied volatility of options 30 days out, the blue line. The band is its 20-session average, 2 standard deviations either side. Realized volatility is how much TARS actually moved over the last 20 sessions, from closing prices, on the same yearly scale. Without earnings takes each earnings report out of the 30-day IV, sized from what options paid for past reports, so it shows whether options are expensive or cheap apart from the report. Click a name above the chart to show or hide it.

Spread Scanner

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Dealer Positioning
TYPICAL γ

Estimated net dealer gamma is at the 80th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
80%
vs own history
GEX tilt
+0.68
OI-weighted, today
Vanna tilt
-0.01
δ-sensitivity to IV
Charm tilt
+0.44
δ-decay vs time
Charm tilt +0.44: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 11 ATM contracts, 1k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Put vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Call vs ATM
IV(call wing) − IV(ATM), in vol points

The same measure on the upside: how the OTM call is priced against the at-the-money strike.

  • Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
  • Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Reading them together

Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d put —
— pts EXTREME
No data
30 DTE / 10d put —
— pts EXTREME
ATM 61.0% / Put —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)
IV Rank (30 DTE)48.8MediumNov 19

Embed TARS IV rank

TARS's 30-day IV rank (90 sessions) with its 52-week rank, at-the-money IV and a 90-session trend. Updates after each close. Paste the code into any web page or blog post. Email newsletters drop iframes, so link to the page there.

Theme
Preview
Straddle Price (30 DTE)$10.85Nov 19
Beta Analysis

Risk Metrics

Beta: 0.5915
Alpha: 3.62%
Correlation: 0.1812
R-Squared: 3.3%
Stock Volatility: 45.1%
Market Volatility: 13.8%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own TARS
4 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Millennium Management Hedge fund
Izzy Englander
$89.8M
0.06%
#371 of 3716+152.8%13F
Citadel Hedge fund
Ken Griffin
$15.2M
0.01%
#1302 of 6285+47.4%13F
Renaissance Technologies Hedge fund
Jim Simons
$5.7M
0.01%
#1380 of 3151+675.3%13F
Rockefeller Capital Management Family office
Rockefeller family
$111K
0.00%
#2996 of 4858+0.6%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

TARS Institutional Ownership (13F)

Filings for 2026-09-30
Diluted shares outstanding: 43,898,631 (as of 2026-09-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

258 filers47,171,834 shares$3.27B value107.46% of float
# Filer Shares Value % of Total % of Float Period
1 BlackRock, Inc. Custodian 3,866,442 $303.94M 9.31% 8.81% 2026-09-30
2 Deep Track Capital, LP 3,666,768 $230.79M 7.07% 8.35% 2026-06-30
3 RTW INVESTMENTS, LP 3,357,059 $211.29M 6.47% 7.65% 2026-06-30
4 Jupiter Topco LLC 2,808,796 $176.83M 5.41% 6.40% 2026-06-30
5 Paradigm Biocapital Advisors LP 2,775,649 $174.70M 5.35% 6.32% 2026-06-30
6 Vanguard Capital Management LLC 1,879,009 $147.71M 4.52% 4.28% 2026-09-30
7 Morgan Stanley Custodian 1,710,654 $134.47M 4.12% 3.90% 2026-09-30
8 Jennison Associates LLC 1,663,655 $104.71M 3.21% 3.79% 2026-06-30
9 TANG CAPITAL MANAGEMENT LLC 1,568,266 $98.71M 3.02% 3.57% 2026-06-30
10 Millennium Management LLC Custodian 1,427,124 $89.82M 2.75% 3.25% 2026-06-30
11 State Street Corp 1,104,233 $86.80M 2.66% 2.52% 2026-09-30
12 Geode Capital Management, LLC Custodian 1,056,446 $83.06M 2.54% 2.41% 2026-09-30
13 Bank of America Corp Custodian 1,193,182 $75.10M 2.30% 2.72% 2026-06-30
14 Invesco Ltd. Custodian 879,788 $69.16M 2.12% 2.00% 2026-09-30
15 Vestal Point Capital, LP 1,050,000 $66.09M 2.02% 2.39% 2026-06-30
16 Assenagon Asset Management S.A. 615,974 $48.42M 1.48% 1.40% 2026-09-30
17 Goldman Sachs Group Inc Custodian 742,693 $46.75M 1.43% 1.69% 2026-06-30
18 Frazier Life Sciences Management, L.P. 728,644 $45.86M 1.40% 1.66% 2026-06-30
19 D. E. Shaw & Co., Inc. Custodian 710,559 $44.72M 1.37% 1.62% 2026-06-30
20 FMR LLC Custodian 672,949 $42.36M 1.30% 1.53% 2026-06-30
21 Aberdeen Group plc 505,591 $39.74M 1.22% 1.15% 2026-09-30
22 NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 607,272 $38.22M 1.17% 1.38% 2026-06-30
23 UBS Group AG Custodian 471,978 $37.10M 1.14% 1.08% 2026-09-30
24 WASATCH ADVISORS LP 468,041 $36.79M 1.13% 1.07% 2026-09-30
25 Clearbridge Investments, LLC 448,640 $35.27M 1.08% 1.02% 2026-09-30
8 filers$28.68M notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $11.86M 41.37% 2026-06-30
2 Jane Street Group, LLC Custodian $7.93M 27.66% 2026-09-30
3 TORONTO DOMINION BANK $2.96M 10.31% 2026-06-30
4 GROUP ONE TRADING LLC Custodian $2.34M 8.17% 2026-09-30
5 Millennium Management LLC Custodian $1.89M 6.58% 2026-06-30
6 Citadel Advisors LLC Custodian $1.37M 4.76% 2026-06-30
7 Belvedere Trading LLC $235.83K 0.82% 2026-09-30
8 Simplex Trading, LLC Custodian $94.33K 0.33% 2026-09-30
7 filers$37.39M notional
# Filer Notional Value % of Total Period
1 Caption Management, LLC $25.81M 69.01% 2026-06-30
2 GROUP ONE TRADING LLC Custodian $4.72M 12.61% 2026-09-30
3 Susquehanna International Group, LLP Custodian $2.83M 7.57% 2026-06-30
4 Jane Street Group, LLC Custodian $2.41M 6.43% 2026-09-30
5 Simplex Trading, LLC Custodian $801.82K 2.14% 2026-09-30
6 Citadel Advisors LLC Custodian $673.46K 1.80% 2026-06-30
7 Belvedere Trading LLC $157.22K 0.42% 2026-09-30

TARS Insider Trading (Form 4)

Latest: 2026-11-17
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-11-17 Bobak R. Azamian President/CEO and Board Chair Sell (S) −10,000 $80.31 -$803.1K EDGAR
2026-11-05 Neera Clase Chief Commercial Officer Grant (A) +17,265 opt — EDGAR
2026-09-17 Wendy L Yarno Director Exer (M) +302 — EDGAR
2026-09-17 David E I Pyott Director Exer (M) +201 — EDGAR
2026-09-17 William J Phd Link Director Mixed
Sell −12,500 · Exer +201
−12,299 $78.38 -$979.7K EDGAR
2026-09-09 Elizabeth Yeu Lin Chief Medical Officer Sell (S) −13,953 $87.50 -$1.22M EDGAR
2026-09-09 Bobak R. Azamian President/CEO and Board Chair Sell (S) −10,000 $90.56 -$905.6K EDGAR
2026-09-09 Seshadri Neervannan Chief Operating Officer Sell (S) −4,564 $85.00 -$387.9K EDGAR
2026-09-03 Bobak R. Azamian President/CEO and Board Chair Sell (S) −10,000 $80.06 -$800.6K EDGAR
2026-09-03 Elizabeth Yeu Lin Chief Medical Officer Sell (S) −11,578 $77.56 -$898.0K EDGAR
2026-06-29 Bhaskar Chaudhuri Director Grant (A) +6,254 RSU — EDGAR
2026-06-29 Scott W Morrison Director Grant (A) +6,254 RSU — EDGAR
2026-06-29 David E I Pyott Director Grant (A) +7,060 RSU — EDGAR
2026-06-29 Katherine Goodrich Director Grant (A) +6,254 opt — EDGAR
2026-06-29 Andrew D. Goldberg Director Grant (A) +6,254 opt — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

TARS Insider Holdings

14 insiders · @ $77.06
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Bobak R. Azamian President/CEO and Board Chair 851,412 $65.61M -$15.84M 66 2026-11-17
2 William J Phd Link Director 94,487 $7.28M -$6.94M 22 2026-09-17
3 Seshadri Neervannan Chief Operating Officer 79,007 $6.09M -$2.54M 18 2026-09-09
4 Bryan Wahl General Counsel 63,959 $4.93M -$1.67M 17 2026-03-19
5 Aziz Mottiwala Chief Commercial Officer 61,480 $4.74M -$2.87M 24 2026-03-19
6 Jeffrey S Farrow See Remarks 56,801 $4.38M -$2.33M 11 2026-06-17
7 Dianne C. Whitfield Chief Human Resources Officer 35,028 $2.70M -$3.36M 19 2026-03-19
8 Andrew D. Goldberg Director 19,654 $1.51M $19.0K 11 2026-06-29
9 Wendy L Yarno Director 16,956 $1.31M $0 13 2026-09-17
10 Elizabeth Yeu Lin Chief Medical Officer 16,177 $1.25M -$1.95M 18 2026-09-09
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

TARS Board & Officers

As of SEC filings through Nov 17, 2026

Directors 8

Officers 8

Changes in the last 10 years (54)
Nov 1, 2026Neera Clase became Chief Commercial Officer
Feb 18, 2026David E I Pyott became a director
Jan 15, 2025The company announced the departure of Rosemary A Crane from the board in an SEC filing
Nov 13, 2024Katherine Goodrich became a director
Nov 6, 2024Elizabeth Yeu Lin no longer listed as a director in SEC filings
Nov 6, 2024Elizabeth Yeu Lin first listed as Chief Medical Officer in an SEC filing
Mar 11, 2024Jeffrey S Farrow listed as Chief Financial Officer and Chief Strategy Officer (previously Chief Financial Officer and Chief Strategic Officer) in SEC filings
Apr 24, 2023Jeffrey S Farrow became Chief Financial Officer and Chief Strategic Officer
Mar 21, 2023Mark J. Holdbrook reported in an SEC filing no longer being V.P., Clinical Affairs
Dec 16, 2022Bobak R. Azamian listed as President/CEO and Board Chair (previously President and CEO) in SEC filings
Dec 1, 2022The company announced the departure of Michael Ackermann from the board in an SEC filing
Oct 6, 2022Scott W Morrison became a director
May 5, 2022Vivo Capital IX, LLC reported in an SEC filing no longer being a 10% owner
May 5, 2022Vivo Capital Fund IX, L.P. reported in an SEC filing no longer being a 10% owner
Feb 1, 2022Jose M. Trevejo became Chief Medical Officer
Dec 31, 2021Elizabeth Yeu Lin became a director
Aug 11, 2021Rosemary A Crane became a director
Jun 17, 2021Michael Ackermann no longer listed as a 10% owner in SEC filings
May 7, 2021Rtw Investments, LP reported in an SEC filing no longer being a 10% owner
May 7, 2021Roderick Wong reported in an SEC filing no longer being a 10% owner
Not reported recently (3)
  • Jose M. Trevejo · Last reported as Chief Medical Officer in an SEC filing dated Dec 22, 2023
  • Leonard M. Greenstein · Last reported as Chief Financial Officer in an SEC filing dated Apr 21, 2023
  • Jason E. Tester · Last reported as a director in an SEC filing dated Jun 17, 2021
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

TARS Proposed Insider Sales (Form 144)

Latest: 2026-11-13
Last 30d: 1 filing · $802K notice value  ·  Last 90d: 9 filings · $16.2M notice value · 5 unique filers · 78% under 10b5-1 plans

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: Mottiwala Aziz (2, $11.6M) · BOBAK AZAMIAN (2, $1.7M) · Lin Elizabeth Yeu (3, $1.6M) · WILLIAM J LINK (1, $980K) · Neervannan Seshadri (1, $388K)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-11-13 Bobak Azamian Officer 10,000 $801.5K 2026-11-13 Merrill Lynch 10b5-1 EDGAR
2026-09-15 WILLIAM J LINK DIRECTOR 12,500 $979.7K 2026-09-15 MERRILL LYNCH 10b5-1 EDGAR
2026-09-04 Lin Elizabeth Yeu Member of immediate family of any of the foregoing 3,180 $278.2K 2026-09-04 Fidelity Brokerage Services LLC 10b5-1 EDGAR
2026-09-04 Lin Elizabeth Yeu Officer 10,773 $942.6K 2026-09-04 Fidelity Brokerage Services LLC 10b5-1 EDGAR
2026-09-04 Neervannan Seshadri Officer 4,564 $387.9K 2026-09-04 Fidelity Brokerage Services LLC 10b5-1 EDGAR
2026-09-04 BOBAK AZAMIAN OFFICER 10,000 $905.6K 2026-09-04 MERRILL LYNCH 10b5-1 EDGAR
2026-09-01 Mottiwala Aziz Former Officer 77,698 $5.75M 2026-09-01 Fidelity Brokerage Services LLC — EDGAR
2026-09-01 Lin Elizabeth Yeu Officer 4,601 $339.8K 2026-09-01 Fidelity Brokerage Services LLC 10b5-1 EDGAR
2026-08-25 Mottiwala Aziz Former Officer 81,332 $5.84M 2026-08-25 Fidelity Brokerage Services LLC — EDGAR
2026-08-19 Mottiwala Aziz Former Officer 53,043 $3.82M 2026-08-19 Fidelity Brokerage Services LLC — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-03
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Event Link
2026-11-03 Earnings results EDGAR
2026-09-10 Acquisition or sale completed · Other events EDGAR
2026-08-06 Earnings results EDGAR
2026-08-06 Material agreement · Unregistered share sale · Other events EDGAR
2026-08-06 Material agreement · Unregistered share sale · Other events EDGAR
2026-07-13 Director or officer change EDGAR
2026-07-08 Material agreement · Unregistered share sale · Other events EDGAR
2026-06-29 Shareholder vote results EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-11-03 0001819790-26-000076 EDGAR
2026-08-06 0001819790-26-000064 EDGAR
ETF Holders
65 ETFs hold TARS
25 shown · $486.23M total exposure · 0.14% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 FBT First Trust NYSE® Arca® Biotechnology Index Fund First Trust 3.55% $105.6M $3.0B 2026-11-17
2 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.11% $85.6M $75.0B 2026-11-17
3 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $83.4M — 2026-10-31
4 VXF Vanguard Extended Market ETF Vanguard 0.04% $32.8M — 2026-10-31
5 IWO iShares Russell 2000 Growth ETF iShares (BlackRock) 0.23% $30.9M $13.5B 2026-11-17
6 IBB iShares Biotechnology ETF iShares (BlackRock) 0.26% $28.6M $10.9B 2026-11-17
7 PJP Invesco Pharmaceuticals ETF Invesco 3.36% $20.2M — 2026-11-17
8 VTWO Vanguard Russell 2000 ETF Vanguard 0.10% $18.4M — 2026-10-31
9 SCHA Schwab U.S. Small-Cap ETF Nport 0.06% $14.0M — 2026-08-31
10 IHE iShares U.S. Pharmaceuticals ETF iShares (BlackRock) 0.63% $10.7M $1.7B 2026-11-17
11 XPH State Street® SPDR® S&P® Pharmaceuticals ETF SPDR (State Street) 2.00% $10.2M $507.9M 2026-11-17
12 FYC First Trust Small Cap Growth AlphaDEX® Fund First Trust 0.53% $7.1M $1.3B 2026-11-17
13 VHT Vanguard Health Care ETF Vanguard 0.03% $6.9M — 2026-10-31
14 SMLF iShares U.S. Small-Cap Equity Factor ETF iShares (BlackRock) 0.13% $5.4M $4.1B 2026-11-17
15 ITOT iShares Core S&P Total U.S. Stock Market ETF iShares (BlackRock) 0.00% $4.3M $93.0B 2026-11-17
16 SBIO ALPS Medical Breakthroughs ETF Nport 1.64% $3.9M — 2026-08-31
17 VTWG Vanguard Russell 2000 Growth ETF Vanguard 0.21% $3.4M — 2026-10-31
18 FYX First Trust Small Cap Core AlphaDEX® Fund First Trust 0.25% $3.4M $1.3B 2026-11-17
19 GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF Goldman 0.21% $2.2M $1.0B 2026-11-17
20 HAPS Harbor Human Capital Factor US Small Cap ETF Nport 1.03% $1.7M — 2026-07-31
21 SCHB Schwab U.S. Broad Market ETF Nport 0.00% $1.7M — 2026-08-31
22 ESML iShares ESG Aware MSCI USA Small-Cap ETF iShares (BlackRock) 0.06% $1.6M $2.7B 2026-11-17
23 RSSL Global X Russell 2000 ETF Global X 0.11% $1.5M — 2026-11-18
24 BBP Virtus Biotech Etf Nport 1.31% $1.3M — 2026-07-31
25 FHLC Fidelity MSCI Health Care Index ETF Fidelity 0.03% $1.2M $4.1B 2026-11-17
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-15.18
TTM Revenue
$682.20M
TTM Net Income
$-702.70M
TTM Op. Cash Flow
$49.90M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q3 '262026-09-30$194.57M$-668.33M$-14.40$-6.00M
Q2 '262026-06-30$173.91M$-18.55M$-0.43$61.22M
Q1 '262026-03-31$162.05M$-7.65M$-0.16$-24.65M
Q4 '252025-12-31$151.67M$-8.17M$-0.19$19.33M
Q3 '252025-09-30$118.70M$-12.59M$-0.30$18.26M
Q2 '252025-06-30$102.66M$-20.34M$-0.48$-29.39M
Q1 '252025-03-31$78.33M$-25.21M$-0.64$-20.65M
Q4 '242024-12-31$66.41M$-22.93M$-0.59$-22.18M
Q3 '242024-09-30$48.12M$-23.42M$-0.61$-8.65M
Q2 '242024-06-30$40.81M$-33.29M$-0.88$-14.40M
Q1 '242024-03-31$27.61M$-35.73M$-1.01$-37.79M
Q4 '232023-12-31$13.08M$-41.90M$-1.27$-39.34M
Q3 2026 • period ending 2026-09-30 • filed 2026-11-03
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
32.27
P/S
4.92
EV/EBITDA
—
EV/Sales
4.83
ROE
-675.5%
ROA
-139.0%
Div Yield
0.00%
FCF Yield
1.49%
Debt/Equity
0.70
Current Ratio
—
Market Cap
$3.36B
as of 2026-11-19

TARS vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
LLY Eli Lilly & Co. $1.23T 44.0 +45.5% +25.6% 36
JNJ Johnson & Johnson $656.5B 40.6 +7.8% +28.9% 88
AMGN Amgen Inc $240.1B 25.6 +8.2% +34.6% 43
GILD Gilead Sciences Inc $209.6B — +6.5% +37.8% 59
PFE Pfizer Inc. $159.9B 39.6 +1.3% +10.1% 77
REGN Regeneron Pharmaceuticals Inc $97.8B 20.7 +18.6% +20.9% 66
BIIB Biogen Inc. Common Stock $37.2B 106.0 +2.3% +39.4% 100
UTHR United Therapeutics Corp $24.6B 21.3 +1.9% +13.4% 24
TARS Tarsus Pharmaceuticals, Inc. Common Stoc $3.7B — +86.3% −4.6% 47
Peer median $184.8B 39.6 +7.2% +27.3% 63

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.

Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
6.07M
SI % of Float
16.16%
Days to Cover
6.94
Short Vol Ratio
60.2%
Free Float
37.55M
Float %
85.6%
Short interest 2026-10-30 • Short volume 2026-11-18 • Float 2026-08-26